ArticleEating and weight disorders : EWD2021
An empirical examination of appetite hormones and cognitive and behavioral bulimic symptomatology.
Article in Eating and weight disorders : EWD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Bulimia nervosa.Nature reviews. Disease primers · 2026Review
- The emerging role of glucagon-like peptide 1 in binge eating.The Journal of endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeExisting literature has demonstrated that appetite hormones are frequently dysregulated in individuals with bulimic-spectrum eating disorders (BN-EDs). Although dysregulations in appetite hormones may maintain BN-EDs, very limited research has examined the association between dysregulated appetite hormones and cognitive and behavioral bulimic symptoms. We hypothesized that greater frequency of behavioral symptoms and severity of cognitive symptoms of BN-EDs would correlate with greater dysregulation in appetite hormones.
methodsThe association between ghrelin, cortisol, leptin, GLP-1, and amylin levels and eating pathology was examined in treatment-seeking adults with BN-EDs (N = 33). Participants completed bloodwork to assess fasting blood hormone levels and bulimic symptoms were measured by the Eating Disorder Examination. Pearson partial correlations were run to examine the association between hormone levels and eating pathology, controlling for BMI.
resultsContrary to hypotheses, none of the appetite hormones tested were significantly associated with frequency of behavioral ED symptoms (p range = 0.13-0.97, negligible to small effect sizes). Global eating pathology was positively associated with leptin (p = 0.03) and negatively associated with GLP-1 (p = 0.03) and amylin (p = 0.04), with medium effect sizes. Post hoc analyses indicated significantly stronger associations between appetite hormones and cognitive eating pathology than between appetite hormones and frequency of binge eating [GLP-1 (p = 0.02) and amylin (p = 0.02)] or compensatory behaviors [leptin (p = 0.03), GLP-1 (p = 0.02), and amylin (p = 0.04)].
conclusionIn individuals with BN-EDs, appetite hormones may be more strongly associated with cognitive symptoms than behavioral symptoms. LEVEL OF EVIDENCE: Level V, cross-sectional descriptive study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.